GlaxoSmithKline and Alphabet unit Verily (formerly Google Life Sciences) made a splash yesterday when they announced the launch of Galvani Bioelectronics, a company that will build upon GSK’s three years of work to develop tiny nerve-altering devices that might one day be used instead of drugs to treat a variety of diseases. The two companies will invest up to £540 million (more than $700 million) over the next seven years, they said, employing 30 scientists at GSK’s research center in the U.K. and at Verily in South San Francisco.